Login / Signup

Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial.

Rapat PittayanonPanida PiyachaturawatRungsun RerknimitrPiyapan PrueksapanichSupakarn ChaitongratVorarit LertsuwunseriSuphot SrimahachotaVarocha Mahachai
Published in: Journal of gastroenterology and hepatology (2019)
Rebamipide is safe and may prevent peptic ulcers ≥ 5 mm in diameter or those with pigmented spots in patients receiving dual antiplatelets for 1 year (NCT02166008).
Keyphrases
  • double blind
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • clinical trial
  • prognostic factors
  • study protocol
  • placebo controlled
  • randomized controlled trial
  • wound healing